CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 121 enrolled
Drug / intervention
Ivabradinedrug
Likely dose
Ivabradine 7.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02354573
NCT02354573N/ACompleted
CompareCT.gov

A Mechanistic Study to Assess The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)

University of Oxford·interventional·Posted Feb 3, 2015·Updated Feb 4, 2015

In Brief

A clinical study evaluating Ivabradine for Heart Failure. Completed, enrolled 121 participants across 1 site.

Detailed Summary

What is heart failure with normal ejection fraction? The heart contracts (pumps) and relaxes with each heartbeat. In some people with heart failure, the heart contracts normally but there is reduced relaxation of the heart. As a result, people notice a feeling of breathlessness, ankle swelling and fatigue especially on exertion. The investigators feel that patients with reduced or impaired relaxation of the heart have less heart filling time and poor energy utilisation during exercise. Therefore, the investigators are conducting a study to more thoroughly understand the disease condition by giving a drug called ivabradine to reduce the heart rate and hence to increase the heart filling time in these patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited Kingdom
CollaboratorsUniversity of Aberdeen

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2015
Enrollment StartDec 1, 2011
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.4 years ago

Interventions

Ivabradinedrug

All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.